MannKind Collaborates with Rose Pharma on Inhaled Weight Loss Drug Amid Expanding Financial Challenges
On September 9, MannKind Corporation (NASDAQ:MNKD) announced a licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere, an inhaled GLP-1 receptor agonist for weight management. The deal grants MannKind equity stakes, board representation, and royalty rights without requiring it to take on clinical or regulatory responsibilities. ROSE-010 has already completed four human trials showing promising results in reducing caloric intake and managing IBS pain. MannKind's second-quarter revenue rose 43% year-over-year to $109.4 million, driven by recent FDA approvals for Afrezza and Furoscix ReadyFlow. However, the company reported a net loss of $19 million in Q2 2026 compared to a profit of $668,000 in the same period last year. SG&A expenses surged 84% to $58.3 million due to promotional costs and sales force expansion. Despite these challenges, MannKind is leveraging its Technosphere platform into new markets with limited financial risk while navigating a widening cash deficit that fell from $74.9 million at the end of 2025 to $52.9 million by June 30.
Tickers: $MNKD